

**Editor**

Tore K Kvien

Associate Editors

Francis Berenbaum
Hans Bijlsma
David Pisetsky
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 10.377

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2015 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Techem and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.



Receive regular table of contents by email.
Register using this QR code.

Editorial

- 1633** Spreading spondyloarthritis: are ILCs cytokine shuttles from base camp gut?
B Neerinx, D Elewaut, R J Lories

Recommendation

- 1636** Recommendations for the management of autoinflammatory diseases
N M ter Haar, M Oswald, J Jeyaratnam, J Anton, K S Barron, P A Brogan, L Cantarini, C Galeotti, G Grateau, V Henzen, M Hofer, T Kallinik, I Kone-Paut, H J Lachmann, H Ozdogan, S Ozen, R Russo, A Simon, Y Uziel, C Wouters, B M Feldman, S J Vastert, N M Wulffraat, S M Benseler, J Frenkel, M Gattorno, J B Kummerle-Deschner

Review

- 1645** A review of salivary gland histopathology in primary Sjögren's syndrome with a focus on its potential as a clinical trials biomarker
B A Fisher, R M Brown, S J Bowman, F Barone

Clinical and epidemiological research

- 1651** Poorly controlled type 2 diabetes mellitus is associated with a decreased risk of incident gout: a population-based case-control study
S G Bruderer, M Bodmer, S S Jick, C R Meier
- 1659** Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study
C Rakieh, J L Nam, L Hunt, E M A Hensor, S Das, L-A Bissell, E Villeneuve, D McGonagle, R Hodgson, A Grainger, R J Wakefield, P G Conaghan, P Emery
- 1667** A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study
R A Furie, G Leon, M Thomas, M A Petri, A D Chu, C Hislop, R S Martin, M A Scheinberg, for the PEARL-SC Study
- 1676** Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes
A Ruyssen-Wirand, G Guermec, D Nigon, G Tobon, B Jamard, A-C Rat, O Vittecoq, A Cantagrel, A Constantin
- 1684** Identification of patients with gout: elaboration of a questionnaire for epidemiological studies
P Richette, P Clerson, S Bouée, G Chales, M Doherty, R M Flipo, C Lambert, F Lioté, T Poiraud, T Schaeverbeke, T Bardin
- 1691** Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials
M M Ward, L C Guthrie, M I Alba
- 1697** Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial
X Chevalier, P Ravaut, E Maheu, G Baron, A Rialland, P Vergnaud, C Roux, Y Maugars, D Mulleman, C Lukas, D Wendling, P Lafforgue, D Loeuille, V Foltz, P Richette, On behalf of the French section of osteoarthritis
- 1706** Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
I N Bruce, A G O'Keefe, V Farewell, J G Hanly, S Manzi, L Su, D D Gladman, S-C Bae, J Sanchez-Guerrero, J Romero-Diaz, C Gordon, D J Wallace, A E Clarke, S Bernatsky, E M Ginzler, D A Isenberg, A Rahman, J T Merrill, G S Alarcón, B J Fessler, P R Fortin, M Petri, K Steinsson, M A Dooley, M A Khamashta, R Ramsey-Goldman, A A Zoma, G K Sturfelt, O Nived, C Aranow, M Mackay, M Ramos-Casals, R F van Vollenhoven, K C Kalunian, G Ruiz-Irastorza, S Lim, D L Kamen, C A Peschken, M Inanc, M B Urowitz
- 1714** A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease
C H Sibley, A Chioato, S Felix, L Colin, A Chakraborty, N Plass, J Rodriguez-Smith, C Brewer, K King, C Zalewski, H J Kim, R Bishop, K Abrams, D Stone, D Chapelle, B Kost, C Snyder, J A Butman, R Wesley, R Goldbach-Mansky
- 1720** Inflammatory ultrasound features show independent associations with progression of structural damage after over 2 years of follow-up in patients with hand osteoarthritis
M C Kortekaas, W-Y Kwok, M Reijnen, M Kloppenburg
- 1725** Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA)
M Dougados, M Soubrier, E Perrodeau, L Gossec, F Fayet, M Gilson, M-H Cerato, S Pouplin, R-M Flipo, L Chabrefy, G Mouterde, L Euler-Ziegler, T Schaeverbeke, B Fautrel, A Saraux, I Chary-Valckenaere, G Chales, E Denis, P Richette, X Mariette, F Berenbaum, J Sibilia, P Ravaut
- 1734** Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions
M Y Md Yusof, E M Vital, S Das, S Dass, G Arumugakani, S Savic, A C Rawstron, P Emery

MORE CONTENTS ►

EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals Open Access scheme.
See <http://ard.bmj.com/site/about/guidelines.xhtml#open>

C O P E

COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



equator network



When you have finished with this please recycle it

MCOQS

The online version of this article contains multiple choice questions hosted on BMJ Learning.

Basic and translational research

- 1739** Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis
F Ciccia, G Guggino, A Rizzo, L Saieva, S Peralta, AnnaRita Giardina, A Cannizzaro, G Sireci, G De Leo, R Alessandro, G Triolo
- 1748** S100A4 amplifies TGF- β -induced fibroblast activation in systemic sclerosis
M Tomcik, K Palumbo-Zerr, P Zerr, J Avouac, C Dees, B Sumova, A Distler, C Beyer, L A Cerezo, R Becvar, O Distler, M Grigorian, G Schett, L Senolt, J H W Distler
- 1756** A gain of function mutation in *TNFRSF11B* encoding osteoprotegerin causes osteoarthritis with chondrocalcinosis
Y F M Ramos, S D Bos, R van der Breggen, M Kloppenburg, K Ye, E-W E M W Lameijer, R G H H Nelissen, P E Slagboom, I Meulenbelt
- 1763** JNK-dependent downregulation of FoxO1 is required to promote the survival of fibroblast-like synoviocytes in rheumatoid arthritis
A M Grabiec, C Angiolilli, L M Hartkamp, L G M van Baarsen, P P Tak, K A Reedquist
- 1772** Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation
A J Ytterberg, V Joshua, G Reynisdottir, N K Tarasova, D Rutishauser, E Ossipova, A H Hensvold, A Eklund, C M Sköld, J Grunewald, V Malmström, P J Jakobsson, J Rönnelid, L Padyukov, R A Zubarev, L Klareskog, A I Catrina
- 1778** Differential DNA methylation and expression of inflammatory and zinc transporter genes defines subgroups of osteoarthritic hip patients
M D Rushton, D A Young, J Loughlin, L N Reynard

Letters

- 1784** Gleaning relapse risk from B cell phenotype: decreased CD5⁺ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis
D O Bunch, C E Mendoza, L T Aybar, E S Kotzen, K R Colby, Y Hu, S L Hogan, C J Poulton, J L Schmitz, R J Falk, P H Nachman, W F Pendergraft, JulieAnne G McGregor
- 1786** B cell signature contributes to the prediction of RA development in patients with arthralgia
J Lübbbers, S Vosslander, L A van de Stadt, M van Beers-Tas, J G Wesseling, B M E von Blomberg, B I Witte, H J Bontkes, D van Schaardenburg, C L Verweij

Electronic pages

Correspondence

- e50** Ungoutedly time for a change
G Reid
- e51** The effects of a brace for patellofemoral osteoarthritis targeting knee pain and bone marrow lesions were overestimated or not?
C Zeng, S-g Gao, G-h Lei
- e52** Response to: 'The effects of a brace for patellofemoral osteoarthritis targeting knee pain and bone marrow lesions were overestimated or not?' by Zeng *et al*
M Callaghan, M Parkes, D T Felson
- e53** Belimumab and the measurement of fatigue
D Mazzoni
- e54** Response to: 'Belimumab and the measurement of fatigue' by Mazzoni
V Strand, R A Levy, R Cervera, M Petri
- e55** Dual training in general internal medicine and rheumatology: the Irish context
B J Sheane
- e56** Response to 'Dual training in general internal medicine and rheumatology: the Irish context' by Dr Sheane
F Sivera, S Ramiro, J W Bijlsma
- e57** Response to: 'Is chondroitin sulfate plus glucosamine superior to placebo in the treatment of knee osteoarthritis?' by Zeng *et al*
M C Hochberg, on behalf of the MOVES Investigation Group